CHEMOPH

The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Chemo Pharma Labs latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are majorly tied in miscellaneous assets

Chemo Pharma Labs balance sheet is weak and might have solvency issues

The profit is oscillating. The profit of Chemo Pharma Labs is ₹1.2 Crs for Mar 2024, ₹0.05 Crs for Mar 2023 and ₹0.56 Crs for Mar 2022

Yes, The debt of Chemo Pharma Labs is increasing. Latest debt of Chemo Pharma Labs is -₹6.75 Crs as of Sep-24. This is greater than Mar-24 when it was -₹12.21 Crs.

Chemo Pharma Labs is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA. Latest PE of Chemo Pharma Labs is 50.03, while 3 year average PE is 25.83. Also latest EV/EBITDA of Chemo Pharma Labs is 0.0 while 3yr average is 3.02.

Chemo Pharma Labs has given better returns compared to its competitors. Chemo Pharma Labs has grown at ~59.27% over the last 1yrs while peers have grown at a median rate of -4.0%

Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Chemo Pharma Labs is 27.89% and last quarter promoter holding is 27.89%.

There is Insufficient data to gauge this.